



INTERNATIONAL
PATIENT ORGANISATION
FOR PRIMARY IMMUNODEFICIENCIES

14th PID Forum

COVID-19 & PANDEMICS
MANAGEMENT:
PROTECTING THE MOST
VULNERABLE

September 30, 2020, 15:00-16:30

Virtual Forum
Hosted by:
MEP Tomislav Sokol
(EPP, Croatia)





14th PID FORUM

COVID-19 & PANDEMICS MANAGEMENT:
PROTECTING THE MOST VULNERABLE

30 September 2020

15:00 – 16:30

Setting the Scene

- **Martine Pergent**, President of the International Patient Organisation for Primary Immunodeficiencies (IPOPI)



IPOPI 14TH EUROPEAN PID FORUM

COVID-19 & Pandemics

Management:

Protecting the Most

Vulnerable

September 2020

IPOPI cooperative work on COVID-19




As an introduction

- Covid-19 highlights problems that already existed for long
- The pandemic: an eye opener for general public:
 - How is life with a compromised immune system

And also on « old » medicines ...

- Plasma
- Immunoglobulins

We have identified 6 key issues



What helps people with rare conditions is often helpful for all!

General public perception and behaviour

Not aware that there are vulnerable people like people with rare conditions

General prevention guidelines are not harmonised

Emotional-social issue

Patient feel more isolated than ever.

Mental health not taken into account

Lifestyle impact

Information do not always in everyday life

What is true, what is fake news ?

Specific issues and some examples of focus areas

PID Patients & COVID-19 Education

Schools, companies are not aware of, or don't understand vulnerable people

Difficult for a COVID-19 team to reach out the the patients specialist for advice including international specialists (rare diseases)

Access to treatment

Treatment breakdowns, tension on medicines (lgs)


Too much paperwork and nobody to deal with this during shut down

Healthcare systems

No/few specific protocols or procedures for rare diseases

Still no or sudden possibility for home therapy

The pandemic challenges a diverse and complex Stakeholders' ecosystem



What we would love to hear from the different stakeholders?

Information on COVID-19

- Concrete, put into context, useful information, ...
- Harmonised informations

Information on rare diseases specificities:

- What they imply for the general public's behaviour, HCPs' organisation

Communication

- Campaigning on daily best practices
- Fight fake news and activists

Access to hospitals and specialists

- Adapt access to treatment and monitoring

Cooperation

- Research on the virus itself
- Multidisciplinary ways for working and organising, promoting holistic approaches
- Encourage cross boarder harmonized approaches (information sharing, clinics and research, data collection, ...)

Innovation

- Develop new ways for organising (diagnosis, treatment, following up, including home treatment)
- Promote use of new technologies (AI, e-medicine)

Human rights

- Promote health coverage for chronic diseases in every country

Last but not least: Access to treatment

Facing the decline of plasma donations

10%?
20%?
30%?

>Ensure patients can continue to access their IG therapy in an optimal manner

- Especially those with no alternative medicine such as PID patients

>Need to:

- Insure an open and transparent dialogue with all stakeholders
- Insure that appropriate action can be taken anticipatively, including demand management plan to allow prioritisation in case of tension.

Thank you for your attention!

Thank you to the IPOPI Learning Expedition team

- Natalie Helena-Andrews (IPOPI, Portugal)
- Roberta Anido de Pena (Argentina)
- Sian van den Bogaerdt (The Netherlands)
- Carolyn Dews (Australia)
- Magdalena Doragrip (Sweden)
- Christine Jeffery (Australia, IPOPI)
- Igor Koruga (Serbia)
- Julia Nordin (Sweden, IPOPI)
- Vida Ramsak (Slovenia)
- Megan Ryan (USA)
- Kristina Skeries (Canada)
- Leire Solis-Garate (IPOPI, Spain)
- Dimas Sugiharto (Indonesia)



The role of patient organisations during pandemics: discussion with national patient groups

- **Birgit Schlennert**, Deutsche Selbsthilfe Angeborene Immundefekte e.V. (DSAI) (Germany)
- **Izabela Morawska**, Immunoprotect (Poland)
- **Savvas Savva**, Cyprus Primary Association and Friends (Cyprus)
- **Anneli Larsson**, Primaer Immunbrist Organisationen (Sweden)

dsai e.V.
**German Patient Organisation
for Primary Immunodeficiencies**

Challenges and Chances during Corona Pandemic

**IPOPI 14th PID Forum
September 30, 2020**

Overview Germany

- January 27: first case
- mid of March: successive closure of schools, kindergardens in all German states
- March 22: nationwide contact and exit restrictions
- now: restrictions + rules (masks) still in place
 - vary from state to state and week by week
- schools open again with temporarily closures
- cases by Sept. 25: 280.223
deaths: 9.443

Challenge: patients worried with lots of questions

- significant increase of requests, especially at the beginning of the pandemic
 - > first: mostly medical questions
 - > then: also legal, labor law, social law
- no reliable information available
- guideline from German Society for Intensive and Emergency Care
 - > triage: low priority for intensive care beds for patients with „severe and irreversible immunodeficiency“

Solution approach:

- good general guidelines from Robert Koch Institut for Sars Cov2 infection prevention and hygiene measures
- direct approach to PID-doctors and medical societies for reliable statements
> guideline from PID working group API
- sub-area „Corona“ on dsai-Website
> collection of reliable links and data (IPOPI, medical societies etc.)
- virtual Q&A round with a professor
- establish contacts between patients
> similar circumstances, extremely worried vs. optimistic

Still challenging:

- no medically or legally binding guideline, if PID-patients belong to „risk group“
- problem of triage still unsolved
- each patient must discuss individualized „Corona-approach“ with his/her doctor
- for dsai-team: stay updated to have appropriate advisory skills

Challenge: long term perspective for patients

- during first weeks: sick leave often possible, employers sympathetic,
> self-isolation possible or mandatory
- now: resumption of work, back to school
> understanding for situation of PID patients decreases
- existential fear, economic problems
- not only patients facing the problems but also relatives
- psychological problems begin to increase

Solution approach:

- letter to ministries of culture (responsible for school)
- letter to ministries of health

still challenging:

- health and education organized decentralized > no consistent rules
- home office not possible for many jobs
- home-schooling often not possible

Challenge: availability and effectiveness of treatment

- iv-therapy not possible – doctor's offices closed, hospitals focused on preparation for COVID19
- general fear of shortage of plasma/immunoglobulins
- treatment in the future
> vaccination, SARS-Cov2 antibodies

Solution approach:

- unavailability of doctors only short term
- switch from iv-therapy to sc-therapy
- broad awareness campaigns for plasma donation in Germany
- positive aspects: words like immunity, plasma, antibodies now more common in general public > chance to raise awareness



The role of patient organisations during pandemics: discussion with national patient groups

- **Birgit Schlennert**, Deutsche Selbsthilfe Angeborene Immundefekte e.V. (DSAI) (Germany)
- **Izabela Morawska**, Immunoprotect (Poland)
- **Savvas Savva**, Cyprus Primary Association and Friends (Cyprus)
- **Anneli Larsson**, Primaer Immunbrist Organisationen (Sweden)



14th PID forum – the role of patient organisations during pandemics.

Izabela Morawska, Poland

Association for Patients with Primary Immunodeficiencies „IMMUNOPROTECT”

30th September 2020

The less we know the more afraid we are... First days of COVID-19 pandemics

- Fear of unknown
- Disinformation
- Lack of clear government guidelines
- Solution....

The logo for immunoprotect is centered within a white circle that has a green border. The circle is positioned on the right side of the slide, overlapping a dark green vertical bar. The text "immunoprotect" is written in a lowercase, sans-serif font. A small green leaf icon is placed between the words "immun" and "protect".

immunoprotect



immunOprotect

- Guidelines – **12 principles of protection against coronavirus**
- „**How to wear masks**” graphics
- Translation of IPOPI/ESID statements
- **Cooperation with doctors: prof. Sylwia Kołtan, lek. Ewa Stawiarska**
- Webinar - patients were able to ask questions to the doctor, nurse and representative of our association

immunoprotect

WYDZIAŁ MEDYCYNY
KATEDRA
KATEDRA
KATEDRA
KATEDRA
KATEDRA
KATEDRA

12 zasad postępowania pacjentów z PNO w czasie pandemii SARS-Cov-2

📄 📱 📧 📧 📧



316,3K



28,2K
5,2K



Going viral

Psychological issues of lockdown

Stress and fear caused by the pandemic

Lot of people contacted us because they needed someone to support them

Solution: we have introduced a psychologist on-call free of charge to all of the patients in need

The logo for immunoprotect is centered within a white circle that has a green border. The circle is positioned on the right side of the slide, overlapping a dark green vertical bar. The text 'immunoprotect' is written in a lowercase, sans-serif font. A small green leaf icon is placed between the words 'immun' and 'protect'.

Future of IgG treatment?

- Patients were concerned about the future of immunoglobulin treatment
- Solution: **we have published informations based on special government regulations** - including the possibility of receiving the drugs for 6 months, collecting them from a hospital pharmacy by an authorized person or home delivery of medicines
- **We are constantly monitoring availability of the treatment**

The logo for immunoprotect is centered within a white circle that has a green border. The circle is positioned on the right side of the slide, overlapping a dark green vertical bar. The text "immunoprotect" is written in a lowercase, sans-serif font. A small green leaf-like icon is placed between the words "immun" and "protect".

immunoprotect

World PI week

- We have focused on the "I count on you" campaign and on the publication of materials about PID in the media
- We have set up an Instagram account to reach teenage audiences with our content
- **We were trying to remind the importance of social distancing and social responsibility**

The logo for immunoprotect, featuring the word "immunoprotect" in a lowercase, sans-serif font. A small green leaf icon is positioned between the "o" and "p". The logo is centered within a white circle that has a green border. The background of the slide is white on the left and dark green on the right.

immunoprotect

immunoprotect



Prof. dr hab. med. Maciej Siedlar

[Zobacz statystyki](#)

[Promuj](#)



Eva Kanięcińska

[Zobacz statystyki](#)

[Promuj](#)

WORLD PI WEEK



Last but not least

Instead of face-to-face meeting we have introduced the webinar form with GREAT SUCCESS

immunOprotect

To sum up

- The main patients' concerns in Poland were:
 - 1) no reliable scientific data concerning SARS-CoV-2 virus at the beginning of the pandemic
 - 2) confusion caused by the lack of clear rules during a pandemic
 - 3) mental disorders and stress caused by the lockdown
 - 4) fear for the future of the treatment
 - 5) many questions related to work, school and life in the new reality

The logo for immunoprotect is centered within a white circle that has a green border. The word "immunoprotect" is written in a lowercase, sans-serif font. A small green leaf icon is positioned between the "o" and "p" of "protect".

immunoprotect

To sum up

- The main role of our patient organisation during pandemics:
 - 1) transferring reliable scientific knowledge and cooperation with professionals in order to **create clear and transparent rules for the patients**
 - 2) **introduction of psychological support**
 - 3) **taking care of the continuity of the IgG therapeutic program**, constant contact with PID treatment centers and monitoring the availability of the IgG drugs
 - 4) presence in the media, organizing on-line meetings and webinars, constant contact with patients from all over the country

The logo for immunoprotect is centered within a white circle that has a green border. The circle is positioned on the right side of the slide, overlapping a dark green vertical bar. The text 'immunoprotect' is written in a lowercase, sans-serif font. A small green leaf-like icon is placed between the 'm' and 'p' of 'protect'.

Thank you for your attention

The logo for immunoprotect is centered within a white circle that has a green border. The circle is positioned on the right side of the slide, overlapping a dark green vertical bar. The text "immunoprotect" is written in a lowercase, sans-serif font. A small green leaf icon is placed between the words "immun" and "protect".

immunoprotect



The role of patient organisations during pandemics: discussion with national patient groups

- **Birgit Schlennert**, Deutsche Selbsthilfe Angeborene Immundefekte e.V. (DSAI) (Germany)
- **Izabela Morawska**, Immunoprotect (Poland)
- **Savvas Savva**, Cyprus Primary Association and Friends (Cyprus)
- **Anneli Larsson**, Primaer Immunbrist Organisationen (Sweden)



Cyprus Primary Immunodeficiencies and Friends

14th IPOPI PID Forum - COVID-19 & Pandemics Management - Protecting the Most Vulnerable

Online Event

30th of September 2020

Secretary of **Cyprus** PID Association: **Savvas Savva**





COVID19 in Cyprus

First case announced on the 9th of March.

Public events cancelled on the 10th of March

Schools closed on the 13th of March

Work from home or closure of non essential business on the 16th of March

On the 24th of March, a complete national lockdown was enforced.

Reopening in 3 phases, starting on the 4th of May and completed on the 6th of June

Restrictions are still in place. The last few days there is an increase in cases.

Cases 1654 as of 22nd September, 'Deaths' 22.

Cyprus Population 840,000





Protecting the Most Vulnerable – Problems faced

Initial Panic

Confusion fueled by media hype and 'misinformation'

Inconsistencies in comments by doctors and 'specialists'

Restricted access to hospitals and supplies

Psychological issues

Number of PID patients in our Association, 7, (2), (1)

Till today no PID patient has been diagnosed with Covid19





Protecting the Most Vulnerable – Solutions

In collaboration with doctors, hospital staff and the patients, therapies were shifted up to a couple of weeks and medication was provided. No serious problems occurred.

The patients and family members were informed continuously through our Facebook Group with all the government announcements and recommendations by the Health Ministry. Phone calls were made, if needed to have 'direct' contact.

We advised all our patients to work from home as soon as the 1st case was announced and be the last to return to work after the relaxation of the measures.





Protecting the Most Vulnerable – Solutions

We encourage them not to completely isolate and get in touch if any kind of help was needed, even just talking, getting the groceries and take short walks around the neighborhood but keeping distances.

We advised to treat COVID19 as a very contagious and hostile flu bug and is not to be either underestimated or overestimated.

USE COMMON SENSE before acting and avoid spending too much time with the media hype and be careful with all the misinformation on the web, the conspiracy theories etc.





Conclusions

Being an island and the early measures of the government helped to restrict the spread of the virus. Unfortunately, it seems that the number of cases are on the rise. Opening of borders and the relaxed approach from the general public seem to be the main reasons.

The PID patients in Cyprus were not greatly affected but we still advise to be vigilant and follow the recommendations of the Ministry of Health as posted on our Facebook Group page. The association is in constant contact with the Ministry of Health, doctors, working together to ensure that our members are well informed and be prepared if a PID patient is diagnosed with Covid19.

THANK YOU





The role of patient organisations during pandemics: discussion with national patient groups

- **Birgit Schlennert**, Deutsche Selbsthilfe Angeborene Immundefekte e.V. (DSAI) (Germany)
- **Izabela Morawska**, Immunoprotect (Poland)
- **Savvas Savva**, Cyprus Primary Association and Friends (Cyprus)
- **Anneli Larsson**, Primaer Immunbrist Organisationen (Sweden)

The role of patient organisations during pandemics

*Anneli Larsson, Primär immunbristorganisationen,
PIO, Sweden*

Sweden



About PIO

- Established 1978 by Maj-Lis Hellström
- Today 900 members (600 with PID)
- About 20 different PIDs represented
- Office with staff (3 persons, part time)

Overview covid-19 in Sweden

- First case: 31 January
- Recommendations: Keep your distance and take personal responsibility, stay home if you feel unwell, wash your hands often etc., recommendation regarding travels, extra precaution recommended for groups at risk of serious illness, (+ age 70 ect.)
- Restrictions: Ban to visit nursing homes, home study for upper secondary school, college and universities (during spring), ban on public gatherings of more than 50 people, legislation for restaurants, bars, etc
- Cases by Sept. 24: 90 289
- Deaths: 5 878

Plan for the worst and hope for the best

January–February 2020

- Prepared early to change our plans and way to work if the worst would happen.
- Incorporated digital technologies that were new to us in order to communicate with members and among board members (and wrote user friendly manuals in Swedish).
- Decided to hold all meetings **digital** - more members than usual participated at our annual meeting in March!

Challenges faced by persons with PID

March 2020 – The pandemic was a reality

- Worry, fear, many questions to PIO by phone and e-mail.
- The whole world seemed uncertain, many people felt that the world was falling apart.

Challenges faced by persons with PID

Am I at risk of having a severe covid-19 infection due to my PID?

If I get my "normal" infections, will there be room for me at the hospital?


Will I be able to get my Ig-treatment at the hospital?

Will I be safe from being infected with covid-19 at the hospital?


Should I move to a hotel if a family member gets covid-19?

Will there be medicines available?

Can I go to work and earn my living?



Challenges faced by persons with PID



Our role as a patient org. during the pandemic



Meet the need for information and support members in isolation

- Several **zoom meetings** for adult members, lectures and possibility to ask questions to doctors, a nurse, a physiotherapist and a mental coach, small chat groups and craft meetings for children.
- **WHO and the Public Health Agency of Sweden recommendations** shared in our social media!
- **Webinars** with the opportunity ask questions to PID-specialists.
- Information about covid-19 on our **website**, in our **newsletter** and in **social media**.
- Special editions of our **podcast** about covid-19: medical information and member interviews: **“The life in the shadow of covid-19”**.
- **Office with staff:** Possible for members to call or e-mail questions and to just talk.

Lessons learned from the pandemic



- Huge need **for valid information**. But "We don't know yet" is an ok answer.
- In difficult times the need for patient organisations increase:
 - members of all ages have been in contact.
 - need to talk to someone and to "belong".
- Digital meetings bring us together – makes it possible for members with severe conditions to participate that never have before....

Lessons learned from the pandemic

- “Our” doctors and nurses in the eye of the pandemic storm - difficult for us and members to get in contact.
- Lucky to have senior doctors who couldn't work at the hospitals due to covid-19. They provided PIO with information and helped us to answer questions from members and participated in webinars, Podcasts etc.
- IPOPI is really important! Wonderful job with information and webinars!
- Still a long way to go. It isn't over – access to medicines and healthcare still at risk!

Collaboration between doctors, nurses, decision makers and patient organisations will be crucial to fight covid-19 and its consequences.



The challenges of pandemics from a medical and regulator's perspective

- **Nathalie Bere**, Patient Engagement, European Medicines Agency (EMA)
- **Dr Nizar Mahlaoui**, Necker-Enfants Malades Hospital (Paris, France) and Chair of IPOPI's Medical Advisory Panel



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

COVID-19 pandemic: challenges from the regulators point of view

IPOPI PID Forum *“COVID-19 & Pandemics Management: Protecting the Most Vulnerable.”*




COVID-19 challenges

- COVID-19 pandemic is a global crisis, with devastating health, social and economic impact.
- There are no vaccines authorised yet to prevent any human coronavirus infections.
- The key challenge is to develop and approve, as quickly as possible, safe and effective **vaccines** to protect individuals.
- In the meantime effective **treatments** are still needed to manage COVID-19 symptoms and reduce deaths.


Current situation and approach to COVID-19

- Huge worldwide efforts ongoing to develop medicines and make them available as soon as possible; several potential COVID-19 treatments and vaccines are undergoing clinical trials.
- COVID-19 vaccines and treatments must be rigorously tested and meet the same high standards in terms of safety, efficacy and quality, assessed by regulators who will only approve if the benefits are greater than any side effect or potential risks.
- EMA is contributing to global efforts by expediting its processes supporting the development and approval of treatments and vaccines and providing reliable information to patients and healthcare professionals.
- The [COVID-19 EMA pandemic Task Force](#) is a main tool for EMA and the EU medicines regulatory network to enable quick and coordinated regulatory actions. Patient and healthcare professional representatives are part of ETF.

EMA support for development of treatments and vaccines (1)



EMA support for development of treatments and vaccines (2)



Stakeholder engagement: critical for crisis management

- Engagement with patients and healthcare professionals is vital; stakeholder mapping, scenario-planning and impact assessment are critical elements
- EMA can engage rapidly and effectively via its network of patients and healthcare professionals
- Active dissemination of EMA COVID-19 communications is key to increase their effectiveness and ensure EMA is a trusted and regular source of reliable information for patients and healthcare professionals (and help dispel 'false news')
- EMA will continue to hold COVID-19 information sessions for PCWP/HCPWP
- A pool of COVID 'patients' registered at EMA to ensure engagement during upcoming evaluation of medicines/vaccines

Summary



- Key challenge is to develop and approve *safe* and *effective* medicines as quickly as possible
- EMA is supporting rapid development and approval of medicines by expediting its regulatory procedures
- EMA is providing up to date information to patients and healthcare professionals
- EU-wide regulatory network collaboration via EMA COVID Task Force
- International collaboration via ICMRA, WHO, FDA

Any questions?



Further information

Nathalie.bere@ema.europa.eu

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us

Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

Follow us on





The challenges of pandemics from a medical and regulator's perspective

- **Nathalie Bere**, Patient Engagement, European Medicines Agency (EMA)
- **Dr Nizar Mahlaoui**, Necker-Enfants Malades Hospital (Paris, France) and Chair of IPOPI's Medical Advisory Panel

COVID-19 & PANDEMICS MANAGEMENT: PROTECTING THE MOST VULNERABLE

The challenges of pandemics from a medical perspective

IPOPI 14th PID Forum | 2020, Sep. 30th

KNH/UoN A-Project Symposium on Primary Immunodeficiency Disorders:
“Towards Better PID Awareness, Early Diagnosis and Optimal Care”

Dr. Nizar MAHLAOU, M.D., M.P.H., Ph.D.

French national Reference Center for PID (CEREDIH)

Necker-Enfants malade University Hospital

IPOPI MAP Chairman

Contact: nizar.mahlaoui@aphp.fr

[@MahlaouiNizar](https://twitter.com/MahlaouiNizar)



Background

- COVID-19 is a rapidly evolving situation
- Uncertainty about the impact of SARS-CoV-2 infection in individuals with rare diseases
 - Esp. patient populations intuitively at risk of developing severe, such as PIDs.
- Need for collaboration in gathering sound data, sharing informations, communicating

Global Statements & FAQ

- 3 updates since Feb. 10th
 - Translation in many languages
 - English, Arabic, Slovenian, French, Spanish, Polish, Russian, Dutch
- International Medical Advisory Panel



IPOPI COVID-19 Webinars Series



IMPROVING PID PATIENTS' LIVES. WORLDWIDE.

[Home](#) [About IPOPI](#) [Our Work](#) [PIDs](#) [NMOs](#) [Publications](#) [IPOPI PID Map](#) [Media](#) [e-News](#) [IPOPI TV](#) [PID Genius](#)

5TH IPOPI CLINICAL CARE WEBINAR REGISTRATION PAGE

Hyperinflammation in PID explained & how it differs from COVID-19

by Prof Frédéric Rieux-Laucat
Wednesday, May 27 2020 at 14:00h UK time



Professor Frédéric Rieux-Laucat is Director of Research at Inserm and heads the Lab of Immunogenetics of Pediatric Autoimmune Diseases at the Imagine Institute.

Hosted by Mrs Martine Pergent

Recommended browsers
For an optimal experience please use one of the recommended browsers:
Chrome | Firefox | Opera | Safari

Collaborative international research efforts

Buccioli G *et al.* J Allergy Clin Immunol, 2020 Sep. 28th

- 94 patients worldwide
- Risk factors predisposing to severe disease and mortality: similar to the general population.
- Admission rates to ICU tended to be higher
- Median age lower than in the general population.

COPID19

Worldwide survey of COVID-19 in PID patients

[Home](#) | [All the patients](#) |

COPID19
Worldwide survey of COVID-19 in PID patients > Home

COPID19

Worldwide survey of COVID-19 in PID patients

[ClinicalTrials.gov Protocol Record: NCT04459689](#)

With the emergence of SARS-CoV-2 and the COVID-19 pandemic, there is an urgent need to understand the impact of infection on immunodeficient individuals. Whilst co-morbidities (such as diabetes, cancer, arterial hypertension, heart disease...) have been documented in people infected with SARS-CoV-2, there is currently no information on the consequences and outcomes for individuals with primary immunodeficiencies (PID).

Following the 1st phase of the survey (launched by Isabelle Meyts (ESID), Nizar Mahlaoui (CEREDIH & IPOPI) and Kate Sullivan with Stuart Tangye (IUIS), that gave an idea of the number of affected PID patients and the impact of SARS-CoV-2 and directly focusing on obtaining this top level of information), we are launching the 2nd phase: "COPID19".

COPID19 survey is a secured online GDPR compliant platform based in Paris (Imagine Institute). It has been approved by the Paris-Necker-Enfants malades IRB and Ethics Committee. However, this retrospective survey is designed for global distribution. Data can be entered by a health care professional (mostly clinicians) through a personal login and password. Each documenting person will have access to his/her own patients' data. COPID19 require a greater level of information than the 1st phase. The eCRF will be open to evolutions depending on progresses in our knowledge of this pandemic.

Of course, all participating societies and organizations will be acknowledged for their help and input into this initiative.
Thanks in advance for your invaluable contribution to this survey.

All the best,

The COPID19 team:

Nizar Mahlaoui (Paris-Necker, CEREDIH and IPOPI Chair of the IPOPI Medical Advisory Panel)
Fanny Lanternier (Paris-Necker and CEREDIH)
Isabelle Pellier (Angers and CEREDIH)
Alain Fischer (Paris-Necker, CEREDIH, Imagine Institute and Member of the IPOPI Medical Advisory Panel)
Benedicte Neven (Paris-Necker and Imagine Institute)
Jean-Laurent Casanova (Paris-Necker, Imagine Institute and Rockefeller University)
Klaus Warnatz (Frelburg-CCI and Member of the IPOPI Medical Advisory Panel)
Kate Sullivan (Philadelphia and IUIS)
Stu Tangye (Sydney, IUIS and Member of the IPOPI Medical Advisory Panel)
Isabelle Meyts (Leuven, ESID, IUIS and Member of the IPOPI Medical Advisory Panel)

Management of patients

- Schooling/Workplace
- Access to Plasma Derived Medicinal Products (Immunoglobulins, WHO List of Essential Medicines) as PID patients have no alternative therapy
 - High dose regular Ig
 - Hyperimmune Ig
 - Convalescent plasma
- Access to vaccines (for patients and their entourage) — herd immunity
- Psychological/Mental health issues (lockdown in children, etc...) — Coping mechanisms
- Carry accurate informations to patients and caregivers + HCPs (GP, Nurses) + School teachers/Workplace HCPs



Lessons learnt from the pandemic

- **Tomislav Sokol**, Member of the European Parliament, EPP, Croatia
- **Wolfgang Philipp**, DG SANTE C3, Head of Unit of Health Security and Vaccination, European Commission



14th PID FORUM

COVID-19 & PANDEMICS MANAGEMENT:

PROTECTING THE MOST VULNERABLE

30 September 2020

15:00 – 16:30

Concluding remarks

- **Johan Prevot**, International Patient Organisation for Primary Immunodeficiencies (IPOPI)



INTERNATIONAL
PATIENT ORGANISATION
FOR PRIMARY IMMUNODEFICIENCIES

14th PID Forum

COVID-19 & PANDEMICS
MANAGEMENT:
PROTECTING THE MOST
VULNERABLE

September 30, 2020, 15:00-16:30

Virtual Forum
Hosted by:
MEP Tomislav Sokol
(EPP, Croatia)

